Transcript No Slide Title

FDLI Introduction to Medical
Device Law and Regulation
Other Postmarket Controls
Philip Katz
(202) 624-2660
[email protected]
October 29, 2002
Washington, D.C.
Device Tracking



FDCA § 519(e)
21 CFR Part 821 (amended effective May 9, 2002)
“Guidance on Medical Device Tracking” (Jan. 2000)
2
FDCA § 519(e)

Class II or III device



Failure likely to have serious adverse health consequences
Intended to be implanted for more than one year
Life sustaining/supporting device used outside device
user facility
3
Additional Factors



Likelihood of sudden, catastrophic failure
Likelihood of significant adverse clinical outcome
Need for prompt professional intervention
4
Device Tracking


To ensure that device can be traced from
manufacturing facility to patient
Must be able to locate device quickly


Three days for undistributed device
Ten days for device distributed to patient
5
Device Tracking



Separate order issued with PMA approval or 510(k)
clearance
Methods may vary, but must have written SOPs
Can use outside contractor
6
Device Tracking


Must audit system, to verify that it works and
the information is accurate
Must maintain records as long as device is in
distribution or use
7
Device Tracking



Distributors (such as hospitals and other user
facilities) must track and provide information
to the manufacturer
Obligations start/stop at water’s edge
Patient can refuse identifying information
8
Postmarket Surveillance



FDCA § 522
21 CFR Part 822 (effective July 8, 2002)
“Guidance on Criteria and Approaches for
Postmarket Surveillance” (Nov. 1998)
9
FDCA § 522

Class II or III device



Failure likely to have serious adverse health consequences
Intended to be implanted for more than one year
Life sustaining/supporting device used outside device
user facility
10
Other Criteria




Important unanswered surveillance question
Availability of other postmarket mechanisms
Practicality of surveillance strategies
Magnitude of risk
11
Postmarket Surveillance


Limitations of premarket data
Shortcomings of MDRs
12
Postmarket Surveillance



Required by FDA order, not necessarily at time of
review/clearance
Manufacturer must submit plan in 30 days
FDA has 60 days to judge plan’s adequacy
13
Range of Methods



Literature review
Secondary data sets, registries
Studies (clinical, non-clinical)
14
Postmarket Surveillance




Can last up to three years
Applies to foreign manufacturers
Does not apply to devices for export only
Informed consent and IRB requirements apply
15
Postmarket Surveillance




Interim and final reports
Retain records for two years
Produce records within three days
Records subject to inspection/review
16
Device Promotion

Advertising


Not defined, but see drug regulations
Labeling

Label and “all other written, printed or graphic
matter . . . accompanying” the device
17
Device Promotion

Misleading


FDCA § 201(n)
Not just representations made or suggested, but also
material omissions
18
FDCA § 502 – Misbranding

All devices



False or misleading labeling (FDCA § 502(a))
Adequate directions for use, adequate warnings
(FDCA § 502(f))
Registration, listing, 510(f) notice/information
(FDCA § 502(o))
19
FDCA § 502 – Misbranding

Restricted devices


False or misleading advertising (FDCA § 502(q))
Advertising or “other descriptive matter” lacks side
effects, contraindications (FDCA § 502(r))
20
Device Promotion


Unapproved uses
False or misleading statements
21
Unapproved Uses



Promotion of device that is not approved or cleared
Promotion of cleared/approved device for use that
is not cleared or approved
Not limited to advertising/labeling
22
False or Misleading Statements

Shared jurisdiction



FDA – all labeling, restricted device ads
FTC – all other device ads
Sort of
23
False or Misleading Statements

Jurisdiction makes a difference



Different outlooks
Different processes
Different results
24
False or Misleading Statements

FDA



No clear standard
Can look to drug ad regulations
Can look to FTC
25
False or Misleading Statements

FTC


Identifying the representation
Determine whether it’s true and substantiated
26
FTC

Identify the representation



Express and implied claims
Intent irrelevant
Reasonable interpretation by target audience
27
FTC

Is the claim true and substantiated?



Implied presence of substantiation
“Establishment” claims
True + false = false
28
Other Issues


Internet
First Amendment
29
FDLI Introduction to Medical
Device Law and Regulation
Other Postmarket Controls
Philip Katz
(202) 624-2660
[email protected]
October 29, 2002
Washington, D.C.